Inactive Instrument

News Oncolytics Biotech Inc. Toronto S.E.

Equities

CA6823101077

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Oncolytics Biotech Receives German Regulatory Clearance to Evaluate Pelareorep with Modified Folfirinox in Pancreatic Cancer	08:10am	MT
Oncolytics Biotech Brief: Says Received Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer	07:11am	MT
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference	May. 08	PR
Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights	May. 01	AQ
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights	Apr. 30	AQ
Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting	Apr. 26	AQ
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting	Apr. 25	AQ
Oncolytics Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR - Form 6-K	Apr. 12	PU
Oncolytics Biotech Advances toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	Apr. 12	AQ
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA	Apr. 11	CI
Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA	Apr. 11	MT
Oncolytics Biotech Brief: Advancing Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	Apr. 11	MT
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	Apr. 11	PR
Oncolytics Biotech to participate in a Panel Presentation at Canaccord Genuity s Horizons in Oncology Virtual Conference	Apr. 03	AQ
RBC Reiterates Positive Outlook For Oncolytics -- Maintains $6 Target, Outperform/Speculative Risk Rating	Mar. 08	MT
Transcript : Oncolytics Biotech Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Oncolytics Biotech Up 2.9% as Its Fourth-Quarter Loss Narrows on a One-Time Gain	Mar. 07	MT
Oncolytics Biotech Brief: Q4 Net loss for the fourth quarter of 2023 was $3.9 million	Mar. 07	MT
Oncolytics Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
North American Morning Briefing : Powell Still in the Spotlight; ECB Rate Decision Looms	Mar. 07	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oncolytics Biotech Inc. Toronto S.E.

Equities

CA6823101077

Summary

Filters